MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
ANI Pharmaceuticals Operating Cash Flow 2011-2026 | ANIP
Annual Operating Cash Flow ANI Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 M | 119 M | -31.2 M | 3.32 M | 15.3 M | 45.6 M | 67.1 M | 39.4 M | 27.5 M | 17.3 M | 22 M | -5.48 M | -137 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | -31.2 M | 29.5 M |
Quarterly Operating Cash Flow ANI Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 35 M | - | - | 18.3 M | - | - | 21.4 M | - | -26.8 M | -30.4 M | -18.9 M | - | 15.5 M | 20.9 M | 20.7 M | - | 21 M | 22.6 M | 1.71 M | - | 40.8 M | 19 M | 14.3 M | - | 39.8 M | 31.5 M | 22.9 M | - | 23.6 M | 6.53 M | 6.53 M | - | 15.4 M | 14.3 M | 11 M | - | - | - | 1.12 M | - | 11.3 M | 7.13 M | 5.18 M | - | -2.62 M | - | - | - | 422 K | 556 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 40.8 M | -30.4 M | 11.9 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-184 M | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Cabaletta Bio
CABA
|
-53.5 M | $ 3.34 | 0.45 % | $ 3.9 M | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Codexis
CDXS
|
-49.4 M | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.74 | 3.6 % | $ 1.12 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Cerus Corporation
CERS
|
11.4 M | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.87 | -0.39 % | $ 116 M | France |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
CNS Pharmaceuticals
CNSP
|
-17.1 M | $ 3.23 | 2.22 % | $ 1.23 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
329 M | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
142 M | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Amarin Corporation plc
AMRN
|
6.88 M | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-36.1 M | $ 8.41 | -1.87 % | $ 36.4 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
-39.6 M | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
-38.4 M | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
|
Champions Oncology
CSBR
|
7.39 M | $ 6.14 | 3.89 % | $ 83.9 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-28.2 M | $ 0.72 | -2.34 % | $ 4.84 M | USA |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | USA |
 |
Altimmune
ALT
|
-79.8 M | $ 4.21 | -2.32 % | $ 299 M | USA |
 |
CEL-SCI Corporation
CVM
|
-18.8 M | $ 3.88 | -8.92 % | $ 247 M | USA |